A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The fact that cancer is a leading cause of death all around the world has naturally sparked major efforts in the pursuit of novel and more efficient biomarkers that could better serve as diagnostic tools, prognostic predictors, or therapeutical targets in the battle against this type of disease. Mass spectrometry-based proteomics has proven itself as a robust and logical alternative to the immuno-based methods that once dominated the field. Nevertheless, intrinsic limitations of classic proteomic approaches such as the natural gap between shotgun discovery-based methods and clinically applicable results have called for the implementation of more direct, hypothesis-based studies such as those made available through targeted approaches, that might be able to streamline biomarker discovery and validation as a means to increase survivability of affected patients. In fact, the paradigm shifting potential of modern targeted proteomics applied to cancer research can be demonstrated by the large number of advancements and increasing examples of new and more useful biomarkers found during the course of this review in different aspects of cancer research. Out of the many studies dedicated to cancer biomarker discovery, we were able to devise some clear trends, such as the fact that breast cancer is the most common type of tumor studied and that most of the research for any given type of cancer is focused on the discovery diagnostic biomarkers, with the exception of those that rely on samples other than plasma and serum, which are generally aimed toward prognostic markers. Interestingly, the most common type of targeted approach is based on stable isotope dilution-selected reaction monitoring protocols for quantification of the target molecules. Overall, this reinforces that notion that targeted proteomics has already started to fulfill its role as a groundbreaking strategy that may enable researchers to catapult the number of viable, effective, and validated biomarkers in cancer clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments
MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M., Finney, G. L., Frewen, B., Kern, R., Tabb, D. L., Liebler, D. C., & MacCoss, M. J. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq054 · Cited by 4,697
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414 · cited 1×
“One lingering challenge of SRM for candidate biomarker verification is the required sensitivity for quantification of low-abundance proteins, given a dynamic concentration range of plasma proteins of over 12 orders of magnitude (166, 167).”
BackgroundStrimbu, K., & Tavel, J. A. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833ed177 · Cited by 2,062
Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS
Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., & Gygi, S. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0832254100 · Cited by 1,733
Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions
Picotti, P., & Aebersold, R. (2012) · Nature Methods · doi:10.1038/nmeth.2015 · Cited by 1,302 · cited 1×
“One lingering challenge of SRM for candidate biomarker verification is the required sensitivity for quantification of low-abundance proteins, given a dynamic concentration range of plasma proteins of over 12 orders of magnitude (166, 167).”
BackgroundPeterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., & Coon, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.020131 · Cited by 1,288 · cited 1×
“These fragments (product ions) are analyzed in the third quadrupole where they might also be further filtered for specific fragments to be monitored (146, 147).”
BackgroundPoste, G. (2011) · Nature · doi:10.1038/469156a · Cited by 582
A repository of assays to quantify 10,000 human proteins by SWATH-MS
Rosenberger, G., Koh, C. C., Guo, T., Röst, H. L., Kouvonen, P., Collins, B. C., Heusel, M., Liu, Y., Caron, E., Vichalkovski, A., et al. (2014) · Scientific Data · doi:10.1038/sdata.2014.31 · Cited by 413 · cited 1×
“Moreover, the inherent properties of the DIA-based aspect of SWATH-MS allow for indefinite remining of the fragment ion spectra using classic target analysis strategies (152), which theoretically allow for increased robustness in biomarker discovery, as shown in a later part of the present review.”
MethodEdwards, A. M., Isserlin, R., Bader, G. D., Frye, S. V., Willson, T. M., & Yu, F. H. (2011) · Nature · doi:10.1038/470163a · Cited by 411 · cited 2×
“To further corroborate the current state, it has been demonstrated that the bulk of papers reporting findings in specific human proteins are focused on a relatively or disproportionately small number of molecules and that the advent of genome sequencing and the resulting growth in proteomic techniques has not changed…”
BackgroundGuo, T., Kouvonen, P., Koh, C. C., Gillet, L. C., Wolski, W. E., Röst, H. L., Rosenberger, G., Collins, B. C., Blum, L. C., Gillessen, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3807 · Cited by 376
On the Development of Plasma Protein Biomarkers
Surinova, S., Schiess, R., Hüttenhain, R., Cerciello, F., Wollscheid, B., & Aebersold, R. (2011) · Journal of Proteome Research · doi:10.1021/pr1008515 · Cited by 334 · cited 2×
“In reality, different kinds of molecular targets have been used to discover biomarkers in blood/plasma/serum, body fluids, tissues, and their secretions (162).”
BackgroundA complete mass-spectrometric map of the yeast proteome applied to quantitative trait analysis
Picotti, P., Clément-Ziza, M., Lam, H., Campbell, D. S., Schmidt, A., Deutsch, E. W., Röst, H., Sun, Z., Rinner, O., Reiter, L., et al. (2013) · Nature · doi:10.1038/nature11835 · Cited by 318 · cited 2×
“A classical targeted proteomics assay requires specific MS instruments like the triple quadrupole analyzer, where the first and third quadrupoles work as m/z filters, while the second quadrupole acts as a collision cell (146).”
BackgroundMethodBoersema, P. J., Aye, T. T., van Veen, T. A. B., Heck, A. J. R., & Mohammed, S. (2008) · PROTEOMICS · doi:10.1002/pmic.200800297 · Cited by 220
Abbatiello, S. E., Schilling, B., Mani, D. R., Zimmerman, L. J., Hall, S. C., MacLean, B., Albertolle, M., Allen, S., Burgess, M., Cusack, M. P., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047050 · Cited by 215 · cited 1×
“LoD (limit of detection) and LoQ (limit of quantification) values observed in unfractionated plasma were in the high hundreds of nanograms per milliliter to low micrograms per milliliter concentration ranges for target proteins and had a linear dynamic range spanning three orders of magnitude (22).”
BackgroundThe cancer cell secretome: A good source for discovering biomarkers?
Pavlou, M. P., & Diamandis, E. P. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.04.003 · Cited by 200
Applications of targeted proteomics in systems biology and translational medicine
Ebhardt, H. A., Root, A., Sander, C., & Aebersold, R. (2015) · PROTEOMICS · doi:10.1002/pmic.201500004 · Cited by 184
Kennedy, J. J., Abbatiello, S. E., Kim, K., Yan, P., Whiteaker, J. R., Lin, C., Kim, J. S., Zhang, Y., Wang, X., Ivey, R. G., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2763 · Cited by 184
Dephoure, N., & Gygi, S. P. (2012) · Science Signaling · doi:10.1126/scisignal.2002548 · Cited by 153 · cited 2×
“SWATH (151), NeuCode (173), and Hyperplexing (44, 174) may not be already inserted in the clinical trials, but are a step toward the right direction in addressing these aspects.”
Background
Cited by
Plant-derived anticancer agents: A green anticancer approach
Iqbal, J., Abbasi, B. A., Mahmood, T., Kanwal, S., Ali, B., Shah, S. A., & Khalil, A. T. (2017) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2017.10.016 · Cited by 685
Application of Proteomics in Cancer: Recent Trends and Approaches for Biomarkers Discovery
Kwon, Y. W., Jo, H.-S., Bae, S., Seo, Y., Song, P., Song, M., & Yoon, J. H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.747333 · Cited by 268
Clinical potential of mass spectrometry-based proteogenomics
Zhang, B., Whiteaker, J. R., Hoofnagle, A. N., Baird, G. S., Rodland, K. D., & Paulovich, A. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0135-7 · Cited by 210
Froehlich, B. C., Popp, R., Sobsey, C. A., Ibrahim, S., LeBlanc, A. M., Mohammed, Y., Aguilar‐Mahecha, A., Poetz, O., Chen, M. X., Spatz, A., et al. (2020) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.202000034 · Cited by 9
Allgoewer, K., Wu, S., Choi, H., & Vogel, C. (2023) · Molecular Omics · doi:10.1039/d2mo00258b · Cited by 5
Metadata
- Authors
- Faria, S. S., Morris, C. F. M., Silva, A. R., Fonseca, M. P., Forget, P., Castro, M. S., & Fontes, W.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2017-02-20
- Volume
- 7
- Pages
- 13-13
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2587972729
- Cited by
- 58
- References
- 18
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.